Literature DB >> 21317753

High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer.

Akito Hata, Reiko Kaji, Shiro Fujita, Nobuyuki Katakami.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21317753     DOI： 10.1097/JTO.0b013e3181d899bb

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  14 in total

Review 1.  Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future.

Authors:  Claudia Proto; Martina Imbimbo; Rosaria Gallucci; Angela Brissa; Diego Signorelli; Milena Vitali; Marianna Macerelli; Giulia Corrao; Monica Ganzinelli; Francesca Gabriella Greco; Marina Chiara Garassino; Giuseppe Lo Russo
Journal:  Transl Lung Cancer Res       Date:  2016-12

Review 2.  Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors.

Authors:  D Westover; J Zugazagoitia; B C Cho; C M Lovly; L Paz-Ares
Journal:  Ann Oncol       Date:  2018-01-01       Impact factor: 32.976

Review 3.  Long Term Therapeutic Plan for Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutation.

Authors:  Seung Hun Jang
Journal:  Tuberc Respir Dis (Seoul)       Date:  2014-01-29

4.  Favorable response to icotinib in a lung cancer patient with a special mutation at exon 19 of epidermal growth factor receptor.

Authors:  Hua Zheng; Qunhui Wang; Heling Shi; Hongmei Zhang; Fanbin Hu; Baolan Li
Journal:  Thorac Cancer       Date:  2014-07-03       Impact factor: 3.500

Review 5.  EGFR mutation status in brain metastases of non-small cell lung carcinoma.

Authors:  Fanny Burel-Vandenbos; Damien Ambrosetti; Michael Coutts; Florence Pedeutour
Journal:  J Neurooncol       Date:  2012-10-20       Impact factor: 4.130

6.  Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation.

Authors:  Yosuke Togashi; Katsuhiro Masago; Masahide Fukudo; Yasuhiro Tsuchido; Chiyuki Okuda; Young Hak Kim; Yasuaki Ikemi; Yuichi Sakamori; Tadashi Mio; Toshiya Katsura; Michiaki Mishima
Journal:  Cancer Chemother Pharmacol       Date:  2011-06-17       Impact factor: 3.333

7.  Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases.

Authors:  Shuimei Luo; Long Chen; Xiuping Chen; Xianhe Xie
Journal:  Oncotarget       Date:  2015-06-30

8.  Afatinib in Treatment-Naive Patients With EGFR-Mutated Lung Adenocarcinoma With Brain Metastasis: A Case Series.

Authors:  Shih-Hong Li; Meng-Heng Hsieh; Yueh-Fu Fang
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

9.  Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases.

Authors:  Siow Ming Lee; Conrad R Lewanski; Nicholas Counsell; Christian Ottensmeier; Andrew Bates; Nirali Patel; Christina Wadsworth; Yenting Ngai; Allan Hackshaw; Corinne Faivre-Finn
Journal:  J Natl Cancer Inst       Date:  2014-07-16       Impact factor: 13.506

10.  Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.

Authors:  Petra Hoffknecht; Amanda Tufman; Thomas Wehler; Theo Pelzer; Rainer Wiewrodt; Martin Schütz; Monika Serke; Jan Stöhlmacher-Williams; Angela Märten; Rudolf Maria Huber; Nicolas J Dickgreber
Journal:  J Thorac Oncol       Date:  2015-01       Impact factor: 15.609
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.